- The study also showed that patients receiving a 240 mg dose saw a 14% reduction in visceral fat, a 5% reduction in total fat, and a 3% decrease in waist circumference.
- Wave Life Sciences plans to begin a Phase 2a study of WVE-007 in the second quarter of 2026.
- The stock fell below its 200-day moving average for the first time in over three months.
Wave Life Sciences (WVE) drew heavy retail attention after reporting interim Phase 1 data for its obesity drug WVE-007, but the update sent the stock plunging more than 55% after the opening bell on Thursday.
WVE shares fell to their lowest levels in more than 10 months and cracked the crucial 200-day moving average (200-DMA) for the first time since Dec. 8, 2025.
Source: TradingView
Overall Weight Loss Was Modest
At the six-month mark, patients receiving a 240 mg dose saw a 14% reduction in visceral fat, a 5% reduction in total fat, and a 3% decrease in waist circumference. However, total body weight declined by just 1%, a figure that fell short of retail expectations in a highly competitive obesity drug market.
The company said there were 32 participants in the 240 mg trial. WVE-007 is an investigational RNA-based drug to silence the INHBE gene to help reduce fat and improve metabolism.
Wave Life Sciences plans to begin a Phase 2a study of WVE-007 in the second quarter of 2026. The study will track weight, fat levels, and other health markers over 12 months. The company said it expects to see greater fat loss while preserving muscle.
How Did Stocktwits Users React?
Despite the premarket slump, retail sentiment turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.
However, users expressed disappointment with the weight-loss data.
One user compared the company’s trial with obesity drug studies being conducted by other pharmaceutical firms.
Year-to-date, the stock is down 27%.
Read also: Pony AI’s Europe Expansion With Uber, Robotaxi Revenue Surge Draws Retail Buzz
For updates and corrections, email newsroom[at]stocktwits[dot]com.